Search results

Skip to results

Type 1 selected

Type

Status

Status

Last updated

Last updated

Guidance programme

Your search for semiglutide returned no results
Showing 16 to 22 of 22 results for semaglutide

  1. Semaglutide for managing overweight and obesity in children 6 to 11 years [TSID12381]

    Awaiting development Reference number: GID-TA12020 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  2. Semaglutide for treating mild cognitive impairment or mild dementia caused by Alzheimer's disease [ID6635]

    Awaiting development Reference number: GID-TA11847 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  3. Basal insulin icodec–semaglutide for treating type 2 diabetes inadequately controlled with daily basal insulin [TSID11940]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  4. Digital technologies for delivering multidisciplinary weight-management services: early value assessment (HTG700)

    Early value assessment (EVA) guidance on digital technologies for delivering multidisciplinary weight-management services.

    HealthTech guidance
    Last updated
    6 March 2024
    View recommendations

    Sections for HTG700

  5. Overweight and obesity management (NG246)

    This guideline covers the prevention and management of overweight, obesity and central adiposity in children, young people and adults. It brings together and updates all NICE's previous guidelines on overweight and obesity. It does not cover pregnancy.

    NICE guideline
    Last updated
    8 January 2026

    Sections for NG246

  6. Oral semaglutide for managing overweight and obesity [ID6188]

    Discontinued Reference number: GID-TA11149

    Technology appraisal guidance
    Discontinued

  7. Insulin icodec for treating type 2 diabetes [ID6175]

    In development Reference number: GID-TA11104 Expected publication date: TBC

    Technology appraisal guidance
    In development